Yulei Mu

Yulei Mu

Auto-generated profile, based on publicly available information

Yulei Mu

Center for Neuromusculoskeletal Restorative Medicine, InnoHK, HKSTP, Sha Tin, New Territories, Hong Kong SAR 999077, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Tissue Engineering Part B: Reviews
Verified
Journal Article
Closed access
ZZZhen Zhang
Zhen Zhang
YMYulei Mu
Yulei Mu
HZHuiqun Zhou
Huiqun Zhou
HYHang Yao
Hang Yao
DWDong-An Wang
Dong-An Wang
Articular cartilage defects significantly compromise the quality of life in the global population. Although many strategies to repair articular cartilage, including microfracture, autologous osteochondral transplantation, and osteochondral allograft, the therapeutic effects remain suboptimal. In recent years, with the development of cartilage tissue engineering, scientists have continuously improved the formulations of therapeutic cells, biomaterial-based scaffolds, and biological factors, which have opened new avenues for better therapeutics of cartilage lesions. This review focuses on advances in cartilage tissue engineering, particularly in preclinical trials and clinical applications, prospects, and challenges.

9 July 2024 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
YMYulei Mu
Yulei Mu
ZZZhen Zhang
Zhen Zhang
HZHuiqun Zhou
Huiqun Zhou
LMLiang Ma
Liang Ma
DWDong-An Wang
Dong-An Wang
The innovative and efficacious application of nanotechnology for remodeling the glioblastoma (GBM) tumor microenvironment (TME) exhibits promising potential as a therapeutic avenue for GBM treatment.

1 September 2024 in Materials Today Bio
Verified
Journal Article
Open access
YMYulei Mu
Yulei Mu
ZZZhen Zhang
Zhen Zhang
HZHuiqun Zhou
Huiqun Zhou
MJMin Jin
Min Jin
LMLiang Ma
Liang Ma
DWDong-An Wang
Dong-An Wang
Efficient drug delivery across the blood-brain barrier is imperative for treating glioblastoma (GBM). This study utilized the GBM cell membrane to construct a biomimetic targeted nanosystem (GMNPs@AMD/RAPA) that hierarchically releases the CXCR4 antagonist AMD3100 and the mTOR pathway inhibitor rapamycin (RAPA) for reprogramming the tumor immune microenvironment and suppressing the progression of GBM. By initially inhibiting the CXCL12/CXCR4 axis, the tumor microenvironment (TME) was reprogrammed to enhance the infiltration of cytotoxic T lymphocytes (CTLs) into the TME while suppressing tumor cell survival, proliferation, and angiogenesis. Subsequently, through further cellular uptake and degradation of the nanoparticles, the mTOR pathway inhibitor RAPA was released, further suppressing the tumor progression. This study successfully combined chemotherapy and immunotherapy, achieving effective synergistic therapeutic effects, and suppressing the progression of GBM.

21 March 2025 in Regenerative Medicine and Dentistry
Verified
Journal Article
Open access
PDF file
BLBangheng Liu
Bangheng Liu
YMYulei Mu
Yulei Mu
DWDong-An Wang
Dong-An Wang
Perspective Bangheng Liu 1,2, Yulei Mu 2,3 and Dong-An Wang 1,2,* 1 Department of Biomedical Engineering, Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong SAR 999077, China 2 Center for Neuromusculoskeletal Restorative Medicine, InnoHK, HKSTP, Sha Tin, New Territories, Hong Kong SAR 999077, China 3 Department of Biomedical Engineering, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong SAR 999077, China * Correspondence: donganwang@cuhk.edu.hk Received: 5 March 2025; Revised: 19 March 2025; Accepted: 20 March 2025; Published: 21 March 2025 Abstract: Induced pluripotent stem cell (iPSC)-derived organoid platforms can simulate various target tissues and hold broad application prospects in personalized medicine, disease modeling, drug screening, organ transplantation, and understanding organ development mechanisms. Currently, the development of human iPSC (hiPSC) organoids is gradually shifting towards Matrigel-free and scaffold-free systems, promoting precise control over the composition and structure of these systems and establishing induction protocols for specialized organoids. Researchers are also exploring the construction of multifunctional systems with complex structures and material exchange channels through vascularization, segmented induction, and assembly technologies, though further breakthroughs are needed. In the future, hiPSC organoids are expected to advance towards personalized precision treatment, high-throughput module detection systems, multi-organ integration, and automation. Additionally, when combined with large artificial intelligence models, there is potential to establish hiPSC data and medical platforms, providing support for drug development and clinical decision-making. Moreover, the development of medical AI is anticipated to foster collaboration rather than competition, promoting coordinated growth in the field. For hiPSC-derived platforms, it is crucial to further enhance the ethical review framework to balance radical scientific exploration with conservative public attitudes. Researchers must also optimize or develop new induction protocols to reduce genomic instability and tumorigenic risks, while avoiding the emergence of non-target cells and insufficient functional maturity.